Online citations, reference lists, and bibliographies.
← Back to Search

Mesothelioma: Scientific Clues For Prevention, Diagnosis, And Therapy

M. Carbone, P. Adusumilli, H. Alexander, P. Baas, F. Bardelli, A. Bononi, R. Bueno, E. Felley-Bosco, F. Galateau-Sallé, D. Jablons, A. Mansfield, Michael Minaai, M. D. de Perrot, P. Pesavento, V. Rusch, D. T. Severson, E. Taioli, A. Tsao, G. Woodard, H. Yang, M. Zauderer, H. Pass
Published 2019 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Mesothelioma affects mostly older individuals who have been occupationally exposed to asbestos. The global mesothelioma incidence and mortality rates are unknown, because data are not available from developing countries that continue to use large amounts of asbestos. The incidence rate of mesothelioma has decreased in Australia, the United States, and Western Europe, where the use of asbestos was banned or strictly regulated in the 1970s and 1980s, demonstrating the value of these preventive measures. However, in these same countries, the overall number of deaths from mesothelioma has not decreased as the size of the population and the percentage of old people have increased. Moreover, hotspots of mesothelioma may occur when carcinogenic fibers that are present in the environment are disturbed as rural areas are being developed. Novel immunohistochemical and molecular markers have improved the accuracy of diagnosis; however, about 14% (high‐resource countries) to 50% (developing countries) of mesothelioma diagnoses are incorrect, resulting in inadequate treatment and complicating epidemiological studies. The discovery that germline BRCA1‐asssociated protein 1 (BAP1) mutations cause mesothelioma and other cancers (BAP1 cancer syndrome) elucidated some of the key pathogenic mechanisms, and treatments targeting these molecular mechanisms and/or modulating the immune response are being tested. The role of surgery in pleural mesothelioma is controversial as it is difficult to predict who will benefit from aggressive management, even when local therapies are added to existing or novel systemic treatments. Treatment outcomes are improving, however, for peritoneal mesothelioma. Multidisciplinary international collaboration will be necessary to improve prevention, early detection, and treatment.
This paper references
10.1097/PAS.0000000000000394
BAP1 Immunohistochemistry and p16 FISH to Separate Benign From Malignant Mesothelial Proliferations
B. Sheffield (2015)
Simian virus 40: the link with human malignant mesothelioma is well established.
M. Carbone (2000)
10.1007/s10552-009-9357-4
Ionizing radiation: a risk factor for mesothelioma
J. Goodman (2009)
Consensus report of the 2015
M Carbone (2016)
10.1016/j.jtho.2016.04.028
Consensus Report of the 2015 Weinman International Conference on Mesothelioma
M. Carbone (2016)
10.1002/ajim.22955
North‐south gradient of mesothelioma and asbestos consumption‐production in the United States‐Progresses since the 1st asbestos partial ban in 1973
Hongbing Sun (2019)
10.1097/JTO.0000000000000471
High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma
Masaki Nasu (2015)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
Global Cancer Observatory: Cancer Today
J Ferlay (2018)
10.1016/j.jtho.2016.09.121
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma
D. Rice (2016)
10.1073/pnas.1105887108
Erionite exposure in North Dakota and Turkish villages with mesothelioma
M. Carbone (2011)
10.1097/PAT.0000000000000181
Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients
S. Liu (2014)
10.1186/1479-5876-10-179
BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs
M. Carbone (2012)
10.1158/1078-0432.CCR-07-5283
Transesophageal Endoscopic Ultrasound with Fine Needle Aspiration in the Preoperative Staging of Malignant Pleural Mesothelioma
K. Tournoy (2008)
10.1016/S1470-2045(15)70056-2
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.
L. Krug (2015)
10.5858/arpa.2017-0124-RA
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.
A. Husain (2018)
10.15585/mmwr.mm6608a3
Malignant Mesothelioma Mortality — United States, 1999–2015
J. Mazurek (2017)
10.1097/JTO.0000000000000506
The Presence of Asbestos in the Natural Environment is Likely Related to Mesothelioma in Young Individuals and Women from Southern Nevada
F. Baumann (2015)
10.1038/sj.bjc.6603293
Factors affecting the mesothelioma detection rate within national and international epidemiological studies: insights from Scottish linked cancer registry-mortality data
D. Camidge (2006)
10.1007/BF02305768
Laparoscopy: An important tool in the staging of malignant pleural mesothelioma
K. Conlon (2006)
10.21037/atm.2017.04.06
The Cappadocia mesothelioma epidemic: its influence in Turkey and abroad.
S. Emri (2017)
10.1016/J.JTCVS.2006.03.068
Positron emission tomography predicts survival in malignant pleural mesothelioma.
R. Flores (2006)
10.1097/PAS.0000000000000825
GATA3 Immunohistochemistry for Distinguishing Sarcomatoid and Desmoplastic Mesothelioma From Sarcomatoid Carcinoma of the Lung
Kyra B. Berg (2017)
10.1038/modpathol.2015.65
BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations
Marta Cigognetti (2015)
10.1016/j.humpath.2015.06.024
BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
Stephanie M. McGregor (2015)
10.5858/arpa.2015-0240-SA
New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?
A. Churg (2016)
10.1080/10408440903044928
Time trend of mesothelioma incidence in the United States and projection of future cases: An update based on SEER data for 1973 through 2005
B. Price (2009)
10.1038/nature22798
BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation
A. Bononi (2017)
10.1016/J.JTHO.2018.08.419
MA12.10 Long-Term Impact of Radiotherapy Before Surgery for Mesothelioma on the Distribution of Memory T Cell Subsets
J. Murakami (2018)
10.1126/science.aaf9011
Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention
C. Tomasetti (2017)
10.1093/carcin/bgz066
Whole-genome sequencing of human malignant mesothelioma tumours and cell lines.
H. Oey (2019)
10.1016/S1470-2045(16)30525-3
Biochemical and imaging surveillance in Li-Fraumeni syndrome - Authors' reply.
A. Villani (2016)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.1183/13993003.01428-2016
Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma
M. D. de Perrot (2017)
10.1186/s12967-014-0301-3
Evaluation of clonal origin of malignant mesothelioma
Sabahattin Comertpay (2014)
10.1016/J.CANRAD.2016.08.036
Does selective pleural irradiation of malignant pleural mesothelioma allow radiation dose escalation
A. Botticella (2016)
10.1016/j.ajpath.2013.07.029
Continuous exposure to chrysotile asbestos can cause transformation of human mesothelial cells via HMGB1 and TNF-α signaling.
Fang Wei Qi (2013)
10.1016/j.jtho.2018.02.021
Progress in the Management of Malignant Pleural Mesothelioma in 2017
Amanda J McCambridge (2018)
10.1007/0-387-28274-2_33
Malignant Mesothelioma Electron Microscopy
R. Fresco (2005)
10.1080/10773525.2015.1122370
Asbestos in commercial cosmetic talcum powder as a cause of mesothelioma in women
R. Lee (2015)
10.1038/modpathol.2017.108
Clinicopathologic and genetic characteristics of young patients with pleural diffuse malignant mesothelioma
M. Vivero (2018)
10.1097/JTO.0b013e318211127a
Pleomorphic Epithelioid Diffuse Malignant Pleural Mesothelioma: A Clinicopathological Review and Conceptual Proposal to Reclassify as Biphasic or Sarcomatoid Mesothelioma
Kyuichi Kadota (2011)
10.1007/s10689-006-9112-x
Improved survival in BRCA2 carriers with ovarian cancer
T. Pal (2006)
10.1038/nature16166
Substantial contribution of extrinsic risk factors to cancer development
Song Wu (2016)
10.1136/oemed-2017-104383
Non-occupational exposure to asbestos and risk of pleural mesothelioma: review and meta-analysis
G. Marsh (2017)
10.1245/s10434-012-2845-x
The Role of Perioperative Systemic Chemotherapy in Diffuse Malignant Peritoneal Mesothelioma Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
M. Deraco (2012)
10.1016/j.jtho.2018.11.006
Does Chromothripsis Make Mesothelioma an Immunogenic Cancer?
M. Carbone (2019)
10.5858/arpa.2017-0365-RA
Malignant Mesothelioma and Its Non-Asbestos Causes.
R. Attanoos (2018)
10.1038/nrc2068
A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes
M. Carbone (2007)
10.1038/s41467-018-05467-z
Evaluating intrinsic and non-intrinsic cancer risk factors
Song Wu (2018)
10.1073/pnas.1612074113
High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma
Yoshie Yoshikawa (2016)
10.18632/oncotarget.10653
Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma
M. Carbone (2016)
10.1002/jcp.22724
Malignant mesothelioma: Facts, Myths, and Hypotheses
M. Carbone (2012)
10.1200/JCO.2018.78.5204
Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma.
V. Panou (2018)
10.1378/chest.11-3204
Postmortem findings of malignant pleural mesothelioma: a two-center study of 318 patients.
Rhian S Finn (2012)
10.1097/JTO.0b013e31826915f1
Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database
V. Rusch (2012)
10.1016/j.surg.2013.01.001
Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma.
H. Alexander (2013)
10.1245/s10434-010-1107-z
Volume-Based Parameter of 18F-FDG PET/CT in Malignant Pleural Mesothelioma: Prediction of Therapeutic Response and Prognostic Implications
H. Lee (2010)
Molecular analyses, morphology and immunohistochemistry together differentiate pleural synovial sarcomas from mesotheliomas: clinical implications.
M. Carbone (2002)
Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin
I Martincorena (2015)
10.1016/0169-5002(95)00508-0
A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group.
V. Rusch (1996)
10.1073/pnas.1821510116
Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy
R. Hassan (2019)
10.1073/pnas.1006542107
Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation
H. Yang (2010)
10.1016/j.molcel.2014.03.002
Autodeubiquitination protects the tumor suppressor BAP1 from cytoplasmic sequestration mediated by the atypical ubiquitin ligase UBE2O.
Nazar Mashtalir (2014)
10.1245/s10434-014-3978-x
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: A Systematic Review and Meta-analysis
J. H. Helm (2014)
10.1136/oemed-2013-101957
High incidence of lung cancer and malignant mesothelioma linked to erionite fibre exposure in a rural community in Central Mexico
M. A. Ortega-Guerrero (2014)
10.1016/j.jtho.2017.04.002
Epidemiology of Environmental Exposure and Malignant Mesothelioma.
Bian Liu (2017)
10.1053/J.SEMDP.2006.08.002
The pathogenesis of mesothelioma.
M. Carbone (2006)
10.1126/science.aaa6806
High burden and pervasive positive selection of somatic mutations in normal human skin
I. Martincorena (2015)
10.1136/oem.2004.018531
The additional risk of malignant mesothelioma in former workers and residents of Wittenoom with benign pleural disease or asbestosis
A. Reid (2005)
10.1016/j.ijheh.2017.07.003
Exposure to naturally occurring mineral fibers due to off-road vehicle use: A review.
C. Wolfe (2017)
10.1038/s41556-018-0178-0
BAP1 links metabolic regulation of ferroptosis to tumor suppression
Yilei Zhang (2018)
10.1093/jnci/djy171
Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide
S. Walpole (2018)
10.1016/S0003-4975(02)04474-0
A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma.
J. Friedberg (2003)
10.1080/10937404.2016.1195322
Environmental risk of mesothelioma in the United States: An emerging concern—epidemiological issues
F. Baumann (2016)
10.1164/RCCM.200412-1731OC
Residential proximity to naturally occurring asbestos and mesothelioma risk in California.
X. Pan (2005)
Role of oxyradicals in mutagenicity and DNA damage induced by crocidolite asbestos in mammalian cells.
A. Xu (1999)
10.1016/j.humpath.2017.07.015
The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center.
A. Marchevsky (2017)
10.1080/10937404.2016.1195321
Investigating palygorskite’s role in the development of mesothelioma in southern Nevada: Insights into fiber-induced carcinogenicity
D. Larson (2016)
10.1111/his.13468
Malignant mesothelioma in situ
A. Churg (2018)
10.1148/radiol.12110872
Malignant pleural disease: diagnosis by using diffusion-weighted and dynamic contrast-enhanced MR imaging--initial experience.
J. Coolen (2012)
10.4149/neo_2014_053
Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma.
H. Kaya (2014)
10.1158/0008-5472.CAN-05-2028
Some oral poliovirus vaccines were contaminated with infectious SV40 after 1961.
Rochelle Cutrone (2005)
10.1007/BF02303538
Intrapleural photodynamic therapy: Results of a phase I trial
H. Pass (2006)
10.1016/j.athoracsur.2014.04.040
Women with malignant pleural mesothelioma have a threefold better survival rate than men.
E. Taioli (2014)
10.1245/s10434-014-3803-6
Current Trends in the Management of Malignant Peritoneal Mesothelioma
J. Miura (2014)
10.1007/s00262-011-1073-8
Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients
K. Suzuki (2011)
10.1093/annonc/mdp307
Malignant peritoneal mesothelioma: a multicenter study on 81 cases.
V. Manzini (2010)
10.21037/tlcr.2017.05.02
Immunotherapy for malignant pleural mesothelioma: current status and future directions.
J. Dozier (2017)
10.1016/j.jss.2015.01.043
Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database.
R. Meyerhoff (2015)
10.17226/10822
Immunization Safety Review
D. Eichmann (2016)
10.1001/jamadermatol.2017.2330
Genotypic and Phenotypic Features of BAP1 Cancer Syndrome: A Report of 8 New Families and Review of Cases in the Literature
A. Haugh (2017)
10.1073/pnas.0604008103
TNF-α inhibits asbestos-induced cytotoxicity via a NF-κB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis
H. Yang (2006)
10.3390/ijms20020429
BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment
A. Guazzelli (2019)
10.1177/1947601910395580
Tissue Tropism of SV40 Transformation of Human Cells: Role of the Viral Regulatory Region and of Cellular Oncogenes.
L. Zhang (2010)
10.1016/j.annepidem.2017.04.001
Epidemiology of mesothelioma of the pericardium and tunica vaginalis testis.
G. Mezei (2017)
10.1136/oem.49.8.566
The mortality of amphibole miners in South Africa, 1946-80.
G. K. Sluis‐Cremer (1992)
10.1378/CHEST.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
10.1097/JTO.0000000000000630
The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification.
W. Travis (2015)
10.1245/s10434-012-2236-3
Combined Diffusion-Weighted and Gadolinium-Enhanced MRI Can Accurately Predict the Peritoneal Cancer Index Preoperatively in Patients Being Considered for Cytoreductive Surgical Procedures
R. N. Low (2012)
10.1097/SLA.0000000000000903
Extrapleural Pneumonectomy in the Treatment of Epithelioid Malignant Pleural Mesothelioma: Novel Prognostic Implications of Combined N1 and N2 Nodal Involvement Based on Experience in 529 Patients
D. Sugarbaker (2014)
10.1016/J.ATHORACSUR.2007.06.066
Malignant pleural mesothelioma: surgical management in 285 patients.
P. Schipper (2008)
10.1038/s41418-018-0213-5
Consensus report of the 8 and 9th Weinman Symposia on Gene x Environment Interaction in carcinogenesis: novel opportunities for precision medicine
M. Carbone (2018)
10.1016/j.athoracsur.2014.09.056
Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma.
E. Taioli (2015)
10.1016/j.jtho.2017.04.020
Improving the Accuracy of Mesothelioma Diagnosis in China.
M. Carbone (2017)
10.1136/oem.48.5.359
On talc, tremolite, and tergiversation.
A. Langer (1991)
TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB–dependent pathway, a possible mechanism for asbestos-induced oncogenesis
H Yang (2006)
10.1378/CHEST.06-1690
Age and sex differences in malignant mesothelioma after residential exposure to blue asbestos (crocidolite).
A. Reid (2007)
10.1016/j.jtho.2016.06.020
BRCA1‐Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study
L. Righi (2016)
10.1126/science.aau3879
Somatic mutant clones colonize the human esophagus with age
I. Martincorena (2018)
10.1126/science.1221711
Loss of the Tumor Suppressor BAP1 Causes Myeloid Transformation
A. Dey (2012)
10.1016/j.canlet.2017.06.028
Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma.
M. Betti (2017)
10.1378/CHEST.129.6.1570
Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a feasibility study of noninvasive assessment, therapeutic follow-up, and possible predictor of improved outcome.
F. Giesel (2006)
10.1038/onc.2015.243
Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma
A. Napolitano (2016)
10.1073/pnas.1309085110
Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair
Helen Yu (2013)
10.1007/s10147-015-0925-1
Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial)
S. Hasegawa (2015)
10.1038/nm.3947
Loss of BAP1 function leads to EZH2-dependent transformation
Lindsay M. LaFave (2015)
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
10.1136/oem.2005.023200
The French National Mesothelioma Surveillance Program
M. Goldberg (2006)
10.1016/j.jtho.2018.06.011
Scientific Advances and New Frontiers in Mesothelioma Therapeutics.
L. Mutti (2018)
10.1038/s41467-018-06854-2
Monoubiquitination of ASXLs controls the deubiquitinase activity of the tumor suppressor BAP1
Salima Daou (2018)
10.1016/j.jtcvs.2015.09.121
Adoption of pleurectomy and decortication for malignant mesothelioma leads to similar survival as extrapleural pneumonectomy.
H. Batırel (2016)
10.1016/j.critrevonc.2016.05.008
Neurofibromatosis type 1 associated low grade gliomas: A comparison with sporadic low grade gliomas.
Jelte Helfferich (2016)
10.1200/JCO.2018.79.0352
A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of BAP1 and Other Germline Mutations.
S. Pastorino (2018)
10.1158/0008-5472.CAN-04-0255
Modern Criteria to Establish Human Cancer Etiology
M. Carbone (2004)
Mesothelioma patients with germline VOLUME 69 | NUMBER 5 | SEPTEMBER/OCTOBER 2019 BAP1 mutations have 7-fold improved long-term survival
F Baumann (2015)
10.1016/j.jtho.2018.04.023
New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi‐Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center
F. Sallé (2018)
10.1001/jamaoncol.2017.2918
Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma
Y. Hung (2018)
10.1073/PNAS.170207097
Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity.
M. Bocchetta (2000)
10.1016/j.humpath.2014.10.015
BAP1 and BRAFV600E expression in benign and malignant melanocytic proliferations.
A. Piris (2015)
10.1016/j.jtho.2016.04.027
North American Multicenter Volumetric CT Study for Clinical Staging of Malignant Pleural Mesothelioma: Feasibility and Logistics of Setting Up a Quantitative Imaging Study
R. Gill (2016)
10.1097/JTO.0000000000000436
Targeted Next-Generation Sequencing of Cancer Genes in Advanced Stage Malignant Pleural Mesothelioma: A Retrospective Study
M. Lo Iacono (2015)
10.1101/381533
Genome-wide silencing screen in mesothelioma cells reveals that loss of function of BAP1 induces chemoresistance to ribonucleotide reductase inhibition: implication for therapy
Agata Okonska (2018)
10.1038/bjc.1997.468
Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies.
P. Baas (1997)
10.1016/j.jtho.2016.06.022
Pleural Effusions from Patients with Mesothelioma Induce Recruitment of Monocytes and Their Differentiation into M2 Macrophages
Anne-Laure Chéné (2016)
Mesothelioma patients with germline CA CANCER
F Baumann (2019)
10.1200/JCO.2009.23.9640
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience.
T. Yan (2009)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/j.jtho.2016.09.124
The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma
V. Rusch (2016)
10.3390/ijerph15030531
Trends and the Economic Effect of Asbestos Bans and Decline in Asbestos Consumption and Production Worldwide
Lucy Allen (2018)
10.1016/j.athoracsur.2009.05.022
Endoscopic ultrasound-guided fine needle aspiration for staging of malignant pleural mesothelioma.
D. Rice (2009)
10.1016/j.bmcl.2017.05.077
Initial evaluation of Cu-64 labeled PARPi-DOTA PET imaging in mice with mesothelioma.
T. Huang (2017)
10.1097/JTO.0b013e3182208e3f
Recommendations for Uniform Definitions of Surgical Techniques for Malignant Pleural Mesothelioma: A Consensus Report of the International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group
D. Rice (2011)
10.1016/0165-4608(89)90105-2
Specificity of asbestos-induced chromosomal aberrations in short-term cultured human mesothelial cells.
K. Olofsson (1989)
10.1016/j.lungcan.2016.09.003
Imaging in pleural mesothelioma: A review of the 13th International Conference of the International Mesothelioma Interest Group.
S. Armato (2016)
Malignant mesothelioma mortality-United States
J M Mazurek (1999)
10.3816/CLC.2005.N.020
Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program.
P. Jänne (2005)
10.1038/jid.2010.302
Sun-induced nonsynonymous p53 mutations are extensively accumulated and tolerated in normal appearing human skin.
P. Ståhl (2011)
10.1038/nrc947
SV40 and human tumours: myth, association or causality?
A. Gazdar (2002)
10.1016/S1470-2045(13)70257-2
Asbestos is not just asbestos: an unrecognised health hazard.
F. Baumann (2013)
10.1007/978-0-387-48993-3_22
Clinical results of cytoreduction and HIPEC for malignant peritoneal mesothelioma.
H. Alexander (2007)
of Clinical Oncology clinical practice guideline
H L Kindler (2018)
10.1016/S1470-2045(17)30169-9
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
E. Alley (2017)
10.1038/ng.912
Germline BAP1 mutations predispose to malignant mesothelioma
J. Testa (2011)
10.1200/JCO.2017.76.6394
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.
H. Kindler (2018)
10.1245/ASO.2003.03.022
Cytoreductive Surgery Combined With Intraoperative Hyperthermic Intrathoracic Chemotherapy for Stage I Malignant Pleural Mesothelioma
S. van Ruth (2003)
10.1016/J.JTHO.2018.08.276
OA08.02 DREAM - A Phase 2 Trial of Durvalumab with First Line Chemotherapy in Mesothelioma: Final Result
A. Nowak (2018)
10.1016/j.jtho.2017.03.023
A Novel BRCA1‐Associated Protein‐1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1‐Mediated DNA Repair
R. Parrotta (2017)
10.1097/CEJ.0000000000000340
Genital use of talc and risk of ovarian cancer: a meta-analysis
Wera Berge (2018)
10.1097/PAT.0b013e3283631cce
Diffuse mesothelioma of the peritoneum: a pathological study of 64 tumours treated with cytoreductive therapy
M. Lee (2013)
10.1016/j.athoracsur.2014.06.024
Thirty-day mortality underestimates the risk of early death after major resections for thoracic malignancies.
Robert R McMillan (2014)
10.2214/AJR.172.4.10587144
Staging of malignant pleural mesothelioma: comparison of CT and MR imaging.
R. Heelan (1999)
Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer
K. Stratton (2002)
10.18632/ONCOTARGET.3487
Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model
Licun Wu (2015)
10.1038/ng.3520
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
R. Bueno (2016)
10.1038/s41419-018-1206-5
BAP1 regulates different mechanisms of cell death
E. B. Affar (2018)
Deep Aspiration Cytology
R M Demay (2011)
The art & science of cytopathology
R. Demay (1996)
10.1165/RCMB.2007-0206OC
HGF mediates cell proliferation of human mesothelioma cells through a PI3K/MEK5/Fra-1 pathway.
Maria E. Ramos-Nino (2008)
10.1016/j.jtho.2018.10.001
Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma
A. Mansfield (2019)
10.1080/10408440701845609
An Evaluation of Reported No-Effect Chrysotile Asbestos Exposures for Lung Cancer and Mesothelioma
J. Pierce (2008)
10.1016/j.humpath.2016.09.026
BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
S. McGregor (2017)
10.1016/j.lungcan.2013.11.026
A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.
C. Cao (2014)
10.32388/pfg7jq
International agency for research on cancer.
J. Higginson (1974)
Genome-based Mutational Analysis by Next Generation Sequencing in Patients with Malignant Pleural and Peritoneal Mesothelioma.
G. Ugurluer (2016)
10.1097/JTO.0000000000000078
A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy: The “SMART” Approach for Resectable Malignant Pleural Mesothelioma
B. Cho (2014)
10.1016/S0140-6736(15)01238-6
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
G. Zalcman (2016)
10 long-term impact of radiotherapy before surgery for mesothelioma on the distribution of memory T cell subsets
J Murakami
10.1158/1078-0432.CCR-11-2259
Molecular Pathways: Targeting Mechanisms of Asbestos and Erionite Carcinogenesis in Mesothelioma
M. Carbone (2011)
10.1245/s10434-013-3358-y
Malignant Peritoneal Mesothelioma: Prognostic Factors and Oncologic Outcome Analysis
D. Magge (2013)
10.1371/journal.pgen.1005633
Combined Genetic and Genealogic Studies Uncover a Large BAP1 Cancer Syndrome Kindred Tracing Back Nine Generations to a Common Ancestor from the 1700s
M. Carbone (2015)
10.1126/science.1260825
Variation in cancer risk among tissues can be explained by the number of stem cell divisions
C. Tomasetti (2015)
Programme national de surveillance du mesotheliome (PNSM)
A Gilg Soit Ilg (2015)
10.18632/oncotarget.22968
Extracellular signal regulated kinase 5 and inflammasome in progression of mesothelioma
Joyce K. Thompson (2018)
Carbon black, titanium dioxide, and talc.
Iarc Monographs (2010)
IMMUNIZATION SAFETY REVIEW COMMITTEE
K. Stratton (2002)
10.1080/2162402X.2015.1009285
The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers
H. Ujiie (2015)
10.1097/PAS.0000000000000616
BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas
H. Hwang (2016)
10.1038/cdd.2017.95
Germline BAP1 mutations induce a Warburg effect
A. Bononi (2017)
10.1158/0008-5472.CAN-04-2260
Shark Cartilage, Cancer and the Growing Threat of Pseudoscience
G. Ostrander (2004)
10.1158/0008-5472.CAN-14-1008
Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.
Guangwu Guo (2015)
10.1158/2159-8290.CD-18-0804
Integrative Molecular Characterization of Malignant Pleural Mesothelioma.
Julija Hmeljak (2018)
10.1038/bjc.2014.478
Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales
A. Linton (2014)
10.1016/j.athoracsur.2016.06.069
A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma.
V. Rusch (2016)
10.1097/JTO.0000000000000181
Supplementary Prognostic Variables for Pleural Mesothelioma
H. Pass (2014)
10.1038/nrc3459
BAP1 and cancer
M. Carbone (2013)
10.1158/1078-0432.CCR-17-0438
In Situ Vaccination after Accelerated Hypofractionated Radiation and Surgery in a Mesothelioma Mouse Model
L. M. de la Maza (2017)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.1016/j.jtho.2018.08.007
Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma
Y. Metaxas (2018)
10.1007/s00280-017-3401-y
Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition
Gayathri Srinivasan (2017)
10.1016/j.ejca.2013.05.027
Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).
D. Baratti (2013)
Whole - genome sequencing of human malignant mesothelioma tumours and cell lines [ published online April 25 , 2019 ]
H Oey
Volumebased parameter of 18)F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications
HY Lee (2010)
10.1038/bjc.2014.418
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
T. Golan (2014)
10.1093/carcin/bgu227
Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.
F. Baumann (2015)
10.1016/S0140-6736(00)04013-7
Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey
Iman Roushdy-Hammady (2001)
10.1001/jamaoncol.2016.5487
Association of Asbestos Exposure With Malignant Mesothelioma Incidence in Eastern China
W. Mao (2017)
10.1016/S1470-2045(17)30891-4
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study
E. Copson (2018)
10.1016/S1470-2045(17)30459-X
Radiotherapy for the treatment of malignant pleural mesothelioma.
M. Perrot (2017)
10.1016/J.JTCVS.2004.10.034
Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications.
J. Erasmus (2005)
10.1016/J.EJCTS.2003.12.001
The case for routine cervical mediastinoscopy prior to radical surgery for malignant pleural mesothelioma.
J. Pilling (2004)
10.1016/j.ejca.2016.06.002
Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study.
V. Képénékian (2016)
Autodeubiquitination protects the tumor suppressor BAP1 from cytoplasmic sequestration mediated by the CA: A Cancer Journal for Clinicians atypical ubiquitin ligase UBE2O
N Mashtalir (2014)
10.1111/1759-7714.12967
Characteristics and long‐term outcomes of advanced pleural mesothelioma in Latin America (MeSO‐CLICaP)
L. Rojas (2019)
10.1016/j.jtho.2016.08.147
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma
A. Nowak (2016)
10.1016/j.jtho.2015.12.108
A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis
F. Brims (2016)
10.1146/annurev-publhealth-031811-124704
The worldwide pandemic of asbestos-related diseases.
L. Stayner (2013)
10.1038/nrc3703
Does everyone develop covert cancer?
M. Greaves (2014)
10.1016/j.jtho.2018.08.2036
Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation
A. Tsao (2018)
10.1038/sj.bdj.2015.91
Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions
J. Dumanski (2015)
10.1097/JTO.0000000000000177
B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis
A. Mansfield (2014)
10.3109/01913129709021930
Analysis of asbestos fiber burden in lung tissue from mesothelioma patients.
R. Dodson (1997)
10.1097/JTO.0b013e31815608d9
Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center
R. Flores (2007)
Whole-genome sequencing of human malignant mesothelioma tumours and cell lines [published online April 25, 2019]. Carcinogenesis
H Oey (2019)



This paper is referenced by
10.1158/2159-8290.CD-19-1220
Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer.
M. Carbone (2020)
10.1038/s41418-019-0418-2
Lipid metabolism offers anticancer treatment by regulating ferroptosis
M. Carbone (2019)
10.3390/cryst10090769
Characterization of Fibrous Mordenite: A First Step for the Evaluation of Its Potential Toxicity
D. Giuseppe (2020)
10.21037/tlcr.2020.02.01
How asbestos and other fibers cause mesothelioma.
G. Gaudino (2020)
10.1038/s41419-020-02940-w
P53-regulated miR-320a targets PDL1 and is downregulated in malignant mesothelioma
C. Costa (2020)
10.21873/anticanres.14494
New Imidazo[2,1-b][1,3,4]Thiadiazole Derivatives Inhibit FAK Phosphorylation and Potentiate the Antiproliferative Effects of Gemcitabine Through Modulation of the Human Equilibrative Nucleoside Transporter-1 in Peritoneal Mesothelioma
Giovanna Li Petri (2020)
10.1101/2020.11.11.355693
Hand2 delineates mesothelium progenitors and is reactivated in mesothelioma
K. Prummel (2020)
10.1016/j.thorsurg.2020.08.005
The Molecular Basis of Malignant Pleural Mesothelioma.
Benjamin Wadowski (2020)
10.1016/j.cllc.2020.06.028
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study.
D. Cortinovis (2020)
10.18632/oncotarget.27341
The phytohormone forchlorfenuron decreases viability and proliferation of malignant mesothelioma cells in vitro and in vivo
Walter Blum (2019)
10.1042/bcj20190622
BAP1 promotes stalled fork restart and cell survival via INO80 in response to replication stress.
H. Lee (2019)
10.3390/cancers12082136
Optimization of a Luciferase-Expressing Non-Invasive Intrapleural Model of Malignant Mesothelioma in Immunocompetent Mice
Elisabeth Digifico (2020)
10.1136/jitc-2019-000461
Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
K. Hotta (2020)
10.1038/s41416-020-0912-9
Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds
Giovanna Li Petri (2020)
10.1002/dc.24395
Effusion cytology of malignant mesothelioma enables earlier diagnosis and recognizes patients with better prognosis.
Sulaf Abd Own (2020)
10.1080/15287394.2019.1694612
Pleural mesothelioma and lung cancer: the role of asbestos exposure and genetic variants in selected iron metabolism and inflammation genes
F. Celsi (2019)
10.21037/tlcr.2019.11.23
Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives.
S. Gray (2020)
10.3389/fonc.2020.00777
Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma
Robert A. Belderbos (2020)
10.1016/j.jtho.2020.01.012
Sensitivity of mesothelioma cells to PARP inhibitors is not dependent on BAP1 but is enhanced by temozolomide in cells with high-Schlafen 11and low-MGMT expression.
Daniel Rathkey (2020)
10.21037/tlcr.2019.11.15
Mesothelioma developing in carriers of inherited genetic mutations.
Yoshie Yoshikawa (2020)
10.1177/1758835920971421
Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma
H. Yang (2020)
10.3390/cells9040888
Detection of Circulating Tumor Cells (CTCs) in Malignant Pleural Mesothelioma (MPM) with the “Universal” CTC-Chip and An Anti-Podoplanin Antibody NZ-1.2
Taiji Kuwata (2020)
10.1016/j.jtho.2019.12.111
Brief Report: Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas.
R. Guo (2019)
10.1098/rsob.200112
RNA editing in mesothelioma: a look forward
Ananya Hariharan (2020)
10.1002/jcp.29414
Data mining analysis of the PP2A cell cycle axis in mesothelioma patients
R. Pippa (2019)
10.1016/j.cllc.2020.07.006
Maintaining Equipoise With Maintenance Therapy in Mesothelioma.
A. Mansfield (2020)
10.3389/fonc.2019.01519
Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future
Fabio Nicolini (2019)
10.1186/s12940-019-0512-4
Asbestos exposure and malignant mesothelioma of the tunica vaginalis testis: a systematic review and the experience of the Apulia (southern Italy) mesothelioma register
L. Vimercati (2019)
10.2174/1871520620666200228110704
Anti-Tumor Effects of Osthole in Different Malignant Tissues: A Review of Molecular Mechanisms.
M. Ashrafizadeh (2020)
10.1038/s41416-019-0661-9
Metabolic rewiring and redox alterations in malignant pleural mesothelioma
L. Urso (2019)
10.1016/j.critrevonc.2020.102949
Extracellular vesicles as biomarkers in malignant pleural mesothelioma: A review.
Tamkin Ahmadzada (2020)
10.1016/j.ebiom.2020.103031
A liquid biopsy for detecting circulating mesothelial precursor cells: A new biomarker for diagnosis and prognosis in mesothelioma
Bill T V Duong (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar